Login Register Cart 0
Generic placeholder image

Current Gene Therapy

Editor-in-Chief

ISSN (Print): 1566-5232
ISSN (Online): 1875-5631

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Identification of HnRNP Family as Prognostic Biomarkers in Five Major Types of Gastrointestinal Cancer

Author(s): Xianghan Chen, Ruining Gong, Jia Wang, Boyi Ma, Ke Lei, He Ren, Jigang Wang, Chenyang Zhao, Lili Wang* and Qian Yu*

Volume 22, Issue 5, 2022

Published on: 10 August, 2022

Page: [449 - 461] Pages: 13

DOI: 10.2174/1566523222666220613113647

open access plus

Abstract

Background: Heterogeneous nuclear ribonucleoproteins (hnRNPs), a large family of RNAbinding proteins, have been implicated in tumor progression in multiple cancer types. However, the expression pattern and prognostic value of hnRNPs in five gastrointestinal (GI) cancers, including gastric, colorectal, esophageal, liver, and pancreatic cancer, remain to be investigated.

Objective: The current research aimed to identify prognostic biomarkers of the hnRNP family in five major types of gastrointestinal cancer.

Methods: Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), and Kaplan-Meier Plotter were used to explore the hnRNPs expression levels concerning clinicopathological parameters and prognostic values. The protein level of hnRNPU was validated by immunohistochemistry (IHC) in human tissue specimens. Genetic alterations of hnRNPs were analyzed using cBioportal, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to illustrate the biological functions of co-expressed genes of hnRNPs.

Results: The vast majority of hnRNPs were highly expressed in five types of GI cancer tissues compared to their adjacent normal tissues, and mRNA levels of hnRNPA2B1, D, Q, R, and U were significantly different in various GI cancer types at different stages. In addition, Kaplan-Meier analysis revealed that the increased hnRNPs expression levels were correlated with better prognosis in gastric and rectal cancer patients (log-rank p < 0.05). In contrast, patients with high levels of hnRNPs exhibited a worse prognosis in esophageal and liver cancer (log-rank p < 0.05). Using immunohistochemistry, we further confirmed that hnRNPU was overexpressed in gastric, rectal, and liver cancers. In addition, hnRNPs genes were altered in patients with GI cancers, and RNA-related processing was correlated with hnRNPs alterations.

Conclusion: We identified differentially expressed genes of hnRNPs in tumor tissues versus adjacent normal tissues, which might contribute to predicting tumor types, early diagnosis, and targeted therapies in five major types of GI cancer.

Keywords: RNA-binding proteins, early diagnosis, GI tract cancers, gene ontology, kyoto encyclopedia of genes and genomes.

« Previous Next »
Graphical Abstract

[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Vangala DB, Cauchin E, Balmaña J, et al. Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. Eur J Cancer 2018; 104: 91-103.
[http://dx.doi.org/10.1016/j.ejca.2018.09.004] [PMID: 30342310]
[3]
Badreddine R, Wang KK. Biomarkers in gastrointestinal cancers. Am J Gastroenterol 2008; 103(8): 2106-10.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01994.x] [PMID: 18637088]
[4]
Wong CC, Li W, Chan B, Yu J. Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers. Semin Cancer Biol 2019; 55: 90-105.
[http://dx.doi.org/10.1016/j.semcancer.2018.04.002] [PMID: 29665409]
[5]
Duffy MJ, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 2014; 134(11): 2513-22.
[http://dx.doi.org/10.1002/ijc.28384] [PMID: 23852704]
[6]
Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020; 159(1): 335-349.e15.
[http://dx.doi.org/10.1053/j.gastro.2020.02.068] [PMID: 32247694]
[7]
Geuens T, Bouhy D, Timmerman V. The hnRNP family: Insights into their role in health and disease. Hum Genet 2016; 135(8): 851-67.
[http://dx.doi.org/10.1007/s00439-016-1683-5] [PMID: 27215579]
[8]
Dreyfuss G, Matunis MJ, Piñol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993; 62(1): 289-321.
[http://dx.doi.org/10.1146/annurev.bi.62.070193.001445] [PMID: 8352591]
[9]
Bampton A, Gittings LM, Fratta P, Lashley T, Gatt A. The role of hnRNPs in frontotemporal dementia and amyotrophic lateral sclerosis. Acta Neuropathol 2020; 140(5): 599-623.
[http://dx.doi.org/10.1007/s00401-020-02203-0] [PMID: 32748079]
[10]
Park YM, Hwang SJ, Masuda K, et al. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4. Mol Cell Biol 2012; 32(20): 4237-44.
[http://dx.doi.org/10.1128/MCB.00443-12] [PMID: 22907752]
[11]
Yu C, Guo J, Liu Y, Jia J, Jia R, Fan M. Oral squamous cancer cell exploits hnRNP A1 to regulate cell cycle and proliferation. J Cell Physiol 2015; 230(9): 2252-61.
[http://dx.doi.org/10.1002/jcp.24956] [PMID: 25752295]
[12]
Vu LP, Prieto C, Amin EM, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 2017; 49(6): 866-75.
[http://dx.doi.org/10.1038/ng.3854] [PMID: 28436985]
[13]
Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: Results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997; 3(12 Pt 1): 2237-46.
[PMID: 9815620]
[14]
Chen X, Gu P, Xie R, et al. Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer. J Cell Mol Med 2017; 21(7): 1266-79.
[http://dx.doi.org/10.1111/jcmm.12999] [PMID: 27862976]
[15]
Wang X, Li Y, Fan Y, Yu X, Mao X, Jin F. PTBP1 promotes the growth of breast cancer cells through the PTEN/Akt pathway and autophagy. J Cell Physiol 2018; 233(11): 8930-9.
[http://dx.doi.org/10.1002/jcp.26823] [PMID: 29856478]
[16]
Yang Y, Wei Q, Tang Y, et al. Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Lett 2020; 475: 43-52.
[http://dx.doi.org/10.1016/j.canlet.2020.01.029] [PMID: 32006618]
[17]
Fei T, Chen Y, Xiao T, et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci USA 2017; 114(26): E5207-15.
[http://dx.doi.org/10.1073/pnas.1617467114] [PMID: 28611215]
[18]
Zhou JM, Jiang H, Yuan T, Zhou GX, Li XB, Wen KM. High hnRNP AB expression is associated with poor prognosis in patients with colorectal cancer. Oncol Lett 2019; 18(6): 6459-68.
[http://dx.doi.org/10.3892/ol.2019.11034] [PMID: 31819776]
[19]
Matsuyama S, Goto Y, Sueoka N, et al. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn J Cancer Res 2000; 91(6): 658-63.
[http://dx.doi.org/10.1111/j.1349-7006.2000.tb00996.x] [PMID: 10874220]
[20]
Yang R, Zeng Y, Xu H, et al. Heterogeneous nuclear ribonucleoprotein K is overexpressed and associated with poor prognosis in gastric cancer. Oncol Rep 2016; 36(2): 929-35.
[http://dx.doi.org/10.3892/or.2016.4845] [PMID: 27278897]
[21]
Guo Y, Zhao J, Bi J, Wu Q, Wang X, Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol 2012; 5(1): 37.
[http://dx.doi.org/10.1186/1756-8722-5-37] [PMID: 22760167]
[22]
Chen L, Zhang J, Chen Q, et al. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Int J Cancer 2020; 147(1): 175-88.
[http://dx.doi.org/10.1002/ijc.32827] [PMID: 31837005]
[23]
Masuda K, Kuwano Y. Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers. Wiley Interdiscip Rev RNA 2019; 10(3): e1520.
[http://dx.doi.org/10.1002/wrna.1520] [PMID: 30479000]
[24]
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45(W1): W98-W102.
[http://dx.doi.org/10.1093/nar/gkx247] [PMID: 28407145]
[25]
Győrffy B, Surowiak P, Budczies J, Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013; 8(12): e82241.
[http://dx.doi.org/10.1371/journal.pone.0082241] [PMID: 24367507]
[26]
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2(5): 401-4.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0095] [PMID: 22588877]
[27]
Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6(269): pl1.
[http://dx.doi.org/10.1126/scisignal.2004088] [PMID: 23550210]
[28]
Jiao X, Sherman BT, Huang W, et al. DAVID-WS: A stateful web service to facilitate gene/protein list analysis. Bioinformatics 2012; 28(13): 1805-6.
[http://dx.doi.org/10.1093/bioinformatics/bts251] [PMID: 22543366]
[29]
Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 2016; 7(31): 49322-33.
[http://dx.doi.org/10.18632/oncotarget.10337] [PMID: 27384994]
[30]
Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018; 5(12): 181006.
[http://dx.doi.org/10.1098/rsos.181006] [PMID: 30662724]
[31]
Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark genes. Sci Rep 2021; 11(1): 6047.
[http://dx.doi.org/10.1038/s41598-021-84787-5] [PMID: 33723286]
[32]
Xing C, Cai Z, Gong J, Zhou J, Xu J, Guo F. Identification of potential biomarkers involved in gastric cancer through integrated analysis of Non-Coding RNA associated competing endogenous RNAs network. Clin Lab 2018; 64(10): 1661-9.
[http://dx.doi.org/10.7754/Clin.Lab.2018.180419] [PMID: 30336538]
[33]
Liang Y, Fan Y, Liu Y, Fan H. HNRNPU promotes the progression of hepatocellular carcinoma by enhancing CDK2 transcription. Exp Cell Res 2021; 409(1): 112898.
[http://dx.doi.org/10.1016/j.yexcr.2021.112898] [PMID: 34737140]
[34]
Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 1999; 96(12): 6745-50.
[http://dx.doi.org/10.1073/pnas.96.12.6745] [PMID: 10359783]
[35]
Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61(7): 3124-30.
[PMID: 11306497]
[36]
Sabates-Bellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007; 5(12): 1263-75.
[http://dx.doi.org/10.1158/1541-7786.MCR-07-0267] [PMID: 18171984]
[37]
Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 2010; 5(10): e13091.
[http://dx.doi.org/10.1371/journal.pone.0013091] [PMID: 20957034]
[38]
Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007; 8(7): R131.
[http://dx.doi.org/10.1186/gb-2007-8-7-r131] [PMID: 17615082]
[39]
Hong Y, Downey T, Eu KW, Koh PK, Cheah PYA. ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 2010; 27(2): 83-90.
[http://dx.doi.org/10.1007/s10585-010-9305-4] [PMID: 20143136]
[40]
D’Errico M, de Rinaldis E, Blasi MF, et al. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 2009; 45(3): 461-9.
[http://dx.doi.org/10.1016/j.ejca.2008.10.032] [PMID: 19081245]
[41]
Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett’s esophagus and adenocarcinoma. Gastroenterology 2006; 131(3): 925-33.
[http://dx.doi.org/10.1053/j.gastro.2006.04.026] [PMID: 16952561]
[42]
Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010; 70(24): 10202-12.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-2607] [PMID: 21159642]
[43]
Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45(4): 938-47.
[http://dx.doi.org/10.1002/hep.21622] [PMID: 17393520]
[44]
Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005; 24(44): 6626-36.
[http://dx.doi.org/10.1038/sj.onc.1208804] [PMID: 16103885]
[45]
Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162(4): 1151-62.
[http://dx.doi.org/10.1016/S0002-9440(10)63911-9] [PMID: 12651607]
[46]
Patry C, Bouchard L, Labrecque P, et al. Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res 2003; 63(22): 7679-88.
[PMID: 14633690]
[47]
Chen Y, Liu J, Wang W, et al. High expression of hnRNPA1 promotes cell invasion by inducing EMT in gastric cancer. Oncol Rep 2018; 39(4): 1693-701.
[http://dx.doi.org/10.3892/or.2018.6273] [PMID: 29484423]
[48]
Li S, Wang W, Ding H, et al. Aptamer BC15 against heterogeneous nuclear ribonucleoprotein A1 has potential value in diagnosis and therapy of hepatocarcinoma. Nucleic Acid Ther 2012; 22(6): 391-8.
[http://dx.doi.org/10.1089/nat.2012.0363] [PMID: 23062008]
[49]
Wang H, Vardy LA, Tan CP, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 2010; 18(1): 52-62.
[http://dx.doi.org/10.1016/j.ccr.2010.04.028] [PMID: 20609352]
[50]
Ji FJ, Wu YY, An Z, et al. Expression of both poly r(C) binding protein 1 (PCBP1) and miRNA-3978 is suppressed in peritoneal gastric cancer metastasis. Sci Rep 2017; 7(1): 15488.
[http://dx.doi.org/10.1038/s41598-017-15448-9] [PMID: 29138420]
[51]
Zhang W, Shi H, Zhang M, et al. Poly C binding protein 1 represses autophagy through downregulation of LC3B to promote tumor cell apoptosis in starvation. Int J Biochem Cell Biol 2016; 73: 127-36.
[http://dx.doi.org/10.1016/j.biocel.2016.02.009] [PMID: 26880484]
[52]
Roychoudhury P, Paul RR, Chowdhury R, Chaudhuri K. HnRNP E2 is downregulated in human oral cancer cells and the overexpression of hnRNP E2 induces apoptosis. Mol Carcinog 2007; 46(3): 198-207.
[http://dx.doi.org/10.1002/mc.20265] [PMID: 17219427]
[53]
Honoré B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H′ show differential expression in normal and selected cancer tissues. Exp Cell Res 2004; 294(1): 199-209.
[http://dx.doi.org/10.1016/j.yexcr.2003.11.011] [PMID: 14980514]
[54]
Yu X, Cao F, Yu Y, et al. HNRNPL is identified and validated as a prognostic biomarker associated with microsatellite instability in human gastric cancer. DNA Cell Biol 2021; 40(10): 1251-60.
[http://dx.doi.org/10.1089/dna.2021.0165] [PMID: 34491823]
[55]
Tian XY, Li J, Liu TH, et al. The overexpression of AUF1 in colorectal cancer predicts a poor prognosis and promotes cancer progression by activating ERK and AKT pathways. Cancer Med 2020; 9(22): 8612-23.
[http://dx.doi.org/10.1002/cam4.3464] [PMID: 33016643]
[56]
Wang YC, Chang KC, Lin BW, et al. The EGF/hnRNP Q1 axis is involved in tumorigenesis via the regulation of cell cycle-related genes. Exp Mol Med 2018; 50(6): 1-14.
[http://dx.doi.org/10.1038/s12276-018-0101-6] [PMID: 29884818]
[57]
Li X, Qian X, Peng LX, et al. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol 2016; 18(5): 561-71.
[http://dx.doi.org/10.1038/ncb3338] [PMID: 27088854]
[58]
Sutaria DS, Jiang J, Azevedo-Pouly ACP, et al. Expression profiling identifies the noncoding processed transcript of HNRNPU with proliferative properties in pancreatic ductal adenocarcinoma. Noncoding RNA 2017; 3(3): E24.
[http://dx.doi.org/10.3390/ncrna3030024] [PMID: 29657295]
[59]
Zhou Y, Liu SX, Zhou YN, Wang J, Ji R. Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus. Eur Rev Med Pharmacol Sci 2021; 25(3): 1339-50.
[PMID: 33629304]
[60]
Ma YL, Peng JY, Zhang P, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009; 8(10): 4525-35.
[http://dx.doi.org/10.1021/pr900365e] [PMID: 19715280]
[61]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[62]
Wu W, Liu Q, Zhang J, Zhao Y. Survey on the current status of the diagnosis and treatment of pancreatic cancer in public tertiary hospitals in China: A cross-sectional questionnaire-based, observational study. J Pancreatol 2021; 4(4): 164-9.
[http://dx.doi.org/10.1097/JP9.0000000000000079]
[63]
Pu N, Lou W, Yu J. PD-1 immunotherapy in pancreatic cancer: Current status. J Pancreatol 2019; 2(1): 6-10.
[http://dx.doi.org/10.1097/JP9.0000000000000010]
[64]
Wu W, Jin G, Wang C, et al. The current surgical treatment of pancreatic cancer in China: A national wide cross-sectional study. J Pancreatol 2019; 2(1): 16-21.
[http://dx.doi.org/10.1097/JP9.0000000000000012]

Rights & Permissions Print Cite
Article Metrics
23
© 2024 Bentham Science Publishers | Privacy Policy